Pramlintide
Also known as: 25B-Amylin, AC137, AM-100, Pramlintide acetate, Symlin, SymlinPen
Source Pramlintide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Pramlintide is a synthetic analogue of the pancreatic hormone amylin, approved in the United States for use as an adjunct to insulin in adults with type 1 diabetes and insulin‑requiring type 2 diabetes. Delivered by subcutaneous injection, it lowers post‑prandial glucose and modestly reduces body weight, making it a candidate for obesity treatment under investigation.
Mechanism of Action
Pramlintide binds to amylin receptors, which are heterodimeric G‑protein‑coupled receptors formed by a calcitonin receptor core and receptor‑activity‑modifying proteins. Activation in brain regions that monitor meal completion slows gastric emptying, suppresses glucagon secretion, and promotes satiety, thereby lowering post‑prandial glucose excursions and reducing caloric intake.
What the Research Shows
Recent narrative and expert reviews describe pramlintide’s dual role in glucose regulation and energy balance. Clinical trials in people with diabetes have documented a weight‑loss effect exceeding 3 % that persisted beyond the treatment period, without major untoward effects. The drug is discussed as a tool to improve insulin resistance in type 1 diabetes, alongside lifestyle measures and other agents. Ongoing investigations explore its use in non‑diabetic obesity, often in combination with other incretin‑based therapies, although development has been limited by dosing frequency and formulation challenges.
Reported Benefits
Evidence from diabetes trials shows pramlintide reduces post‑prandial glucose, curbs glucagon spikes, and produces modest weight loss (≥3 %). In type 1 diabetes, it may help mitigate insulin resistance when added to insulin regimens. Early obesity studies suggest it can aid weight reduction without serious side effects, supporting its potential as a component of multi‑agent weight‑loss strategies.
Limitations of the Evidence
The weight‑loss benefit is modest compared with newer agents, and long‑acting amylin analogues are being pursued to overcome frequent dosing requirements. Clinical data on pramlintide for obesity in people without diabetes remain limited, and most studies are small or early‑phase. Its utility in routine practice is constrained by the need for subcutaneous injection and the absence of large, definitive obesity trials.
Safety Considerations
Pramlintide is generally well tolerated; trials report no major untoward effects, but gastrointestinal symptoms such as nausea are common, especially at higher doses. When combined with insulin, there is an increased risk of hypoglycaemia, requiring careful dose adjustment. Injection‑site reactions have also been observed. Safety concerns have contributed to slower development of amylin‑based anti‑obesity products.
How It Is Administered
The drug is supplied as a sterile solution for subcutaneous injection, typically administered before meals using a pre‑filled pen or vial. Dosing is individualized and often titrated upward to minimise gastrointestinal side effects. Because it must be injected, patient training on proper technique and storage is required.
Routes of Administration
Goals & Uses
- Weight managementBody CompositionModerate
- HbA1c reductionGlycemic ManagementHigh
- Satiety inductionAppetite RegulationModerate
- Glucagon suppressionGlycemic ManagementHigh
- Glycemic control in type 2 diabetesMetabolicHigh
- Glycemic control in type 1 diabetesMetabolic / EndocrineHigh
- Postprandial glucose controlGlycemic ManagementHigh
Contraindications
- Hypersensitivity to pramlintide or excipientsImmunologicalHigh
- Poor adherence to insulin regimenBehavioralModerate
- Severe gastroparesisGastrointestinalModerate
- Confirmed gastroparesisGastrointestinalHigh
- Hypersensitivity to pramlintide or any excipientsAllergyHigh
- Hypoglycemia unawarenessEndocrine/MetabolicHigh
Adverse Effects
- Severe hypoglycemiaEndocrine/MetabolicUncommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Hypoglycemia (when combined with insulin)MetabolicCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalUncommonForceful expulsion of stomach contents
- AnorexiaMetabolicCommon
Drug Interactions
- Insulin (mealtime)High
- InsulinHighMay increase risk of low blood sugar
- Other glucose‑lowering agentsModerate
- Alpha-glucosidase inhibitors (e.g., acarbose)Moderate
- Oral medications requiring rapid GI absorption (e.g., analgesics, antibiotics)Moderate
- Anticholinergic agentsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patients (<18 years)AgeRelative
- Pediatric patients (<16 years)AgeAbsolute
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Adjunct to insulin therapy in type 1 diabetes, Adjunct to insulin therapy in type 2 diabetesEMA approval.
- United StatesApprovedApproved: Adjunct to insulin therapy in type 1 diabetes, Adjunct to insulin therapy in type 2 diabetesFDA approval 2005.
- United KingdomApprovedApproved: Adjunct to insulin therapy in type 1 diabetes, Adjunct to insulin therapy in type 2 diabetesMHRA approval.
FDA‑approved (2005) for type 1 and type 2 diabetes; also approved in EU and UK. Marketed under the brand name Symlin.
Evidence & Sources
- Journal ArticleModerateEržen S, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModeratePanou T, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateApostolopoulou M, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateWalker CS, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateSecher A, Lutz TA, Raun K2026-01-01T00:00:00.000000Z
- Journal ArticleModerateHay DL, et al.2015-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is pramlintide officially approved to treat?
Pramlintide is FDA‑approved as an adjunct to insulin therapy for adults with type 1 diabetes and for insulin‑requiring type 2 diabetes, helping to control post‑prandial glucose.
Can pramlintide be used for weight loss in people without diabetes?
Clinical studies have shown modest weight loss (about 3 % of body weight) in diabetic patients, and early trials suggest potential in non‑diabetic obesity, but it is not yet approved for that indication.
What are the most common side effects of pramlintide?
The most frequently reported adverse effects are nausea and other gastrointestinal symptoms; hypoglycaemia can occur when the drug is combined with insulin, and injection‑site irritation may be seen.
How is pramlintide administered?
It is given by subcutaneous injection, usually before meals, using a pre‑filled pen or vial. Dosing is titrated gradually to improve tolerance.
Why has development of amylin‑based obesity drugs been challenging?
Key challenges include the need for frequent injections, formulation stability, and a safety profile that balances efficacy with gastrointestinal side effects, prompting research into longer‑acting analogues.
What is Pramlintide?
Pramlintide is a synthetic analogue of the pancreatic hormone amylin, approved in the United States for use as an adjunct to insulin in adults with type 1 diabetes and insulin‑requiring type 2 diabetes. Delivered by subcutaneous injection, it lowers post‑prandial glucose and modestly reduces body weight, making it a candidate for obesity treatment under investigation.
What is Pramlintide used for?
Pramlintide is educationally associated with: Weight management, HbA1c reduction, Satiety induction, Glucagon suppression, Glycemic control in type 2 diabetes, Glycemic control in type 1 diabetes, Postprandial glucose control. Educational only — not medical advice.
How is Pramlintide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Pramlintide?
Reported adverse effects include: Severe hypoglycemia, Injection site reactions, Headache, Hypoglycemia (when combined with insulin), Nausea, Vomiting, Anorexia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Pramlintide?
Recorded contraindications: Hypersensitivity to pramlintide or excipients, Poor adherence to insulin regimen, Severe gastroparesis, Confirmed gastroparesis, Hypersensitivity to pramlintide or any excipients, Hypoglycemia unawareness. Consult a qualified clinician before use.